Controlled Release Salbutamol Tablets versus Sustained Release Theophylline Tablets in the Control of Reversible Obstructive Airways Disease

Abstract

A crossover pilot study was undertaken to compare the acceptability of controlled release salbutamol tablets (8 mg twice daily) with a sustained release theophylline preparation (400–800 mg given once each night) in patients with reversible obstructive airways disease. A 2-week run-in period was used to titrate the theophylline dosage. Patients were then allocated at random to one of the treatments before being immediately crossed over to the other for a further 4 weeks. Thirty-two patients, aged 17–66 years, entered the trial. Seventeen patients (53%) were withdrawn. The majority of the 13 withdrawals due to side-effects of theophylline occurred during the run-in period. There were no statistically significant differences between treatments for either lung function tests performed at the clinic or for peak expiratory flow rate recorded by the patients. The non-asthma symptom score was significantly higher with theophylline than with the salbutamol preparation. A preference for treatment with the controlled release salbutamol tablets was expressed by 11/15 patients.

Keywords

Chronic obstructive airways disease salbutamol theophylline controlled release sustained release acceptability

Get full access to this article

View all access options for this article.

References

Herrman

Aynesworth

Martin

: Successful treatment of persistent extreme dyspnoea “status asthmaticus”. J Lab Clin Med 1937; 23: 135–148.

Woodcock

Johnson

Geddes

: Theophylline prescribing, serum concentrations, and toxicity. Lancet 1983; ii: 610–613.

Jenne

Wyze

Rood

: Pharmacokinetics of theophylline. Application to adjustment of the clinical dose of aminophylline. Clin Pharmacol Ther 1972; 13: 349–360.

Vozeh

Kewitz

Perruchoud

: Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: the optimal use of intravenously administered aminophylline. Am Rev Respir Dis 1982; 125: 181–184.

Woodcock

Johnson

Geddes

: Theophylline prescribing, serum levels and toxicity. Thorax 1983; 38: 240.

Rall

: Central nervous system stimulants—the methylxanthines. In: The Pharmacological Basis of Therapeutics ( Gilman

Goodman

Rall

, eds), 7th edn. New York: MaCmillan, 1985; pp 589–603.

Barnes

Greening

Neville

: Single-dose, slow release aminophylline at night prevents nocturnal asthma. Lancet 1982; i: 299–301.

Horn

Clark

Cochrane

: Inhaled therapy reduces morning dips in asthma. Lancet 1984; i: 1143–1145.

Sykes

Reese

Meyer

: Pharmacokinetic properties of a new sustained release albuterol preparation, Volmax. J Allergy Clin Immunol 1987; 79: 152.

10.

Maesen

FPV

Smeets

: Comparison of a controlled-release tablet of salbutamol given twice daily with a standard tablet given four times daily in the management of chronic obstructive lung disease. Eur J Clin Pharmacol 1986; 31: 431–436.

11.

Hills

Armitage

: The two-period crossover clinical trial. Br J Clin Pharmacol 1979; 8: 7–20.

12.

Dahl

: A multicentre trial of salbutamol controlled release tablets (Volmax®) and standard salbutamol tablets (Ventolin®) in the management of asthma and chronic bronchitis. Eur Respir J 1988; 1: 206S.